# Avrobio

Avrobio is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** avrobio.com
- **LinkedIn:** https://www.linkedin.com/company/avrobio

## Regulatory record

- **Reports private funds:** No

## About

AVROBIO is a biotechnology company founded in 2015 in Cambridge, Massachusetts. It specializes in gene therapy, modifying hematopoietic stem cells to produce therapeutic proteins. AVROBIO's pipeline includes clinical and preclinical programs for genetic disorders.

## Sectors

- Biotech

## People

- Geoff MacKay — President and CEO

## Questions

### Which diseases does Avrobio target in its active pipeline?

Avrobio’s clinical pipeline currently focuses on Fabry disease and cystinosis. The Fabry disease program, AVR-RD-01, uses ex vivo lentiviral gene therapy to deliver a functional GLA gene into a patient’s hematopoietic stem cells. The cystinosis program, AVR-RD-04, targets the CTNS gene mutation. Avrobio previously included Gaucher disease and Hunter syndrome programs but discontinued the Gaucher Type 1 arm in 2023 after interim clinical data.

### How does Avrobio’s plato® platform work?

The plato® platform is Avrobio’s proprietary lentiviral vector manufacturing system designed to maintain transgene stability during large-scale production. Standard lentiviral vectors are prone to genetic rearrangements that can compromise the therapeutic payload, an issue that has affected multiple gene therapy companies. Plato® reduces this instability by optimizing vector design and production, aiming to preserve consistent potency across batches.

### Who runs clinical development decisions at Avrobio?

CEO Geoff MacKay has led Avrobio since its founding in 2015 and is the central decision-maker on pipeline prioritization. The departure of Chief Medical Officer Dr. Essa Quinton in 2023 left a gap in the clinical leadership, and the company has since consolidated operational oversight under a smaller executive team.

### How does Avrobio compare to peers like bluebird bio or Orchard Therapeutics?

Avrobio competes in the ex vivo lentiviral gene therapy field but targets a distinct disease cluster: lysosomal storage disorders, rather than the hemoglobinopathies and immunodeficiencies that dominate bluebird bio and Orchard Therapeutics' portfolios. This narrower focus avoids direct competition in larger indications but faces the same modality-specific challenges around vector durability and manufacturing complexity.

### Has Avrobio ever partnered with a larger pharmaceutical company?

Publicly disclosed records do not indicate a major strategic partnership with a large pharmaceutical company. Avrobio has historically funded its pipeline through public equity markets and internal research, with no announced licensing or co-development deals.

## Related profiles

- [Exro Technologies](https://altss.com/profile/exro-technologies-inc)
- [TAS Partners](https://altss.com/profile/tas-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/avrobio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology